Therapeutic Potential of Baicalein in Endometrial Cancer: Suppression of mTOR Signaling and Synergy with Metformin
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211061 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Alison L Dumitriu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: Metformin, Flavanones, Endometrial Neoplasms, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute of the National Institutes of Health, Panda Charitable Foundation.
Abstract (Originalsprache)
Baicalein, a natural flavonoid derived from traditional medicinal herbs, has demonstrated anticancer activity in various malignancies, but its role in endometrial cancer remains largely unexplored. In this study, we investigated the therapeutic potential of baicalein, alone and in combination with metformin, in human endometrial cancer cells. Given that the mTOR signaling pathway is frequently dysregulated in endometrial cancer due to PTEN loss, we examined how baicalein affects this pathway. Our results demonstrated that baicalein significantly inhibited cell proliferation in a dose-dependent manner, which was associated with increased DDIT4 expression, activation of AMPK, and decreased phosphorylation of mTOR downstream targets S6K1 and S6. In vivo, baicalein treatment led to a reduction in tumor volume in HEC-1A xenograft female nude mice without affecting body weight. While metformin also reduced cell viability, baicalein achieved comparable effects at lower concentrations. The combination of baicalein and metformin produced a synergistic anti-tumor effect and more effectively inhibited the AMPK/PI3K/mTOR signaling pathway than either agent alone. These findings suggest that baicalein may represent a promising, non-toxic therapeutic option for endometrial cancer, particularly when used in combination with metformin. Further investigation is warranted to assess the clinical relevance of this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
- Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
ORCID-Profile: Alison L Dumitriu, Ernest S Han
Förderung
- National Cancer Institute of the National Institutes of Health
- Panda Charitable Foundation
Zitieren
APA
Dumitriu, A. L., Wen, W., Yan, J., Xing, Q., Ro, F. E., Han, E. S., & Yim, J. H. (2025). Therapeutic Potential of Baicalein in Endometrial Cancer: Suppression of mTOR Signaling and Synergy with Metformin. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211061
Vancouver
Dumitriu AL, Wen W, Yan J, Xing Q, Ro FE, Han ES, et al. Therapeutic Potential of Baicalein in Endometrial Cancer: Suppression of mTOR Signaling and Synergy with Metformin. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211061
BibTeX
@article{Dumitriu2025,
author = {Dumitriu, Alison L and Wen, Wei and Yan, Jin and Xing, Quanhua and Ro, Finn E and Han, Ernest S and Yim, John H},
title = {Therapeutic Potential of Baicalein in Endometrial Cancer: Suppression of mTOR Signaling and Synergy with Metformin},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211061}
}
EUVIMED